Mounjaro injection reviews: what the clinical evidence actually shows

The SURMOUNT-1 results: what the numbers behind the reviews mean

When people share their Mounjaro injection reviews online, the weight-loss figures can sound almost too large to be real. They are, in fact, grounded in one of the most closely watched obesity trials in recent memory. SURMOUNT-1 recruited 2,539 adults with obesity or overweight plus a weight-related condition; participants received Mounjaro or placebo over 72 weeks alongside a reduced-calorie diet and activity programme. At the 15 mg maintenance dose, average body-weight reduction was around 20–21%, with roughly a third of participants losing more than a quarter of their starting weight.

Two things are worth holding onto when reading those numbers. First, the trial population followed a structured lifestyle programme alongside the injection, results reflect medicine plus behaviour change, not the injection alone. Second, SURMOUNT-1 used a stepped titration that began at 2.5 mg, a dose whose job is to settle the digestive system rather than produce therapeutic effect. The titration schedule, and decisions about whether and when to increase your dose, sit entirely with your prescriber. NICE reviewed this evidence before recommending tirzepatide in TA1026, published in December 2024.

A separate trial, SURMOUNT-5, compared tirzepatide head-to-head with semaglutide 2.4 mg in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. That comparison matters because many people considering Mounjaro injection reviews UK are weighing it against Wegovy, and randomised evidence now exists for that question. You can read a broader comparison of weight-loss treatment options to see how the medicines sit alongside each other.

What the injection itself involves, and what arriving patients often tell us

The Mounjaro KwikPen is a pre-filled, disposable device with a small concealed needle. Each pen contains four once-weekly doses at the same strength. Injection sites are the abdomen, upper thigh or upper arm; rotating between sites each week is recommended to reduce localised reactions. The needle is fine and short, and a question our prescribers hear regularly is whether it hurts, for most people, the answer is very little, especially compared with what they expected.

Storage is in a refrigerator at 2–8 °C. For the precise room-temperature window that applies if you need to travel with it, the Mounjaro Patient Information Leaflet is the authoritative source; our page on how the Mounjaro injection works covers the practical steps in detail. The injection site guidance page goes further on rotation technique and what to do if you notice mild redness at the site.

When an order is dispatched through a regulated online pharmacy, the pen arrives via DPD next working day in plain, unbranded packaging, you get a tracking notification the evening before, so there is no waiting by the door. Disposing of used needles safely matters; a 1-litre sharps container keeps that straightforward at home.

Side effects: what the evidence says and when to get medical help

The most common side effects reported in SURMOUNT-1 were gastrointestinal: nausea, vomiting, diarrhoea and constipation. For most participants these were mild to moderate and were most prominent in the days after starting treatment or after a dose increase, easing as the body adapted. Eating smaller portions, avoiding very fatty meals and staying well hydrated can help reduce the intensity; your prescriber and the Patient Information Leaflet will give specific guidance.

One side effect that carries a more serious signal is pancreatitis. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging acute pancreatitis as an infrequent but potentially serious risk. The symptom to act on is severe, persistent abdominal pain that may spread to the back, with or without vomiting, that warrants urgent medical attention, not a wait-and-see approach. A full overview of taking Mounjaro safely covers when to seek help and what to tell a clinician. Any suspected side effect can also be reported directly to the MHRA at yellowcard.mhra.gov.uk.

Mounjaro is not suitable during pregnancy, while breastfeeding or if you are actively trying to conceive. It is not licensed for people under 18. Women taking oral contraceptives should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying in a way that can reduce how much of the pill is absorbed.

Who the licensed eligibility criteria apply to, and how a private route differs from the NHS

Under its UK licence, Mounjaro can be prescribed for adults with a BMI of 30 or above, or from 27 with at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. BMI is the starting point; the prescriber then reviews the whole picture.

NICE's recommendation in TA1026 sets a different, narrower bar for NHS prescribing, a BMI of 35 or above with at least one qualifying comorbidity, within a phased rollout that began in June 2025. Many people reading weight loss injections Mounjaro reviews are doing so precisely because the NHS criteria do not yet apply to them, or because waiting lists are long. A private regulated pharmacy route means no referral and no queue, subject to clinical suitability. Pricing context and what a legitimate private prescription includes are explained on the Mounjaro prescription page. Our prescribers at nume's clinical team (sorry, at nume's clinical team) review each consultation personally, the same day it is submitted.

If you are ready to find out whether Mounjaro is clinically appropriate for you, check your eligibility through a free consultation, and you can also read tirzepatide injection reviews from patients who have been through the same process.